ScreenerHero

IBRXImmunityBio Inc

NAS · US · Healthcare · Biotechnology · immunitybio.com
7.790USD-4.18%Mkt Cap: 8.26B $P/E: —

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against c…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap8.26B $
Enterprise Value9.18B $
Revenue (TTM)165.79M $
Gross Profit112.53M $
Net Income (TTM)-351.40M $
Revenue/Share0.1650 USD
Last Price7.790 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees684
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS45256X1037
Valuation
P/E (Trailing)—
P/E (Forward)-61.89
PEG—
EV/EBITDA-39.02
EV/Revenue55.38
P/S50.12
P/B-7.89
EPS (TTM)-0.92
EPS (Forward)-0.13
52W Range
1.95056% of range12.43
52W High12.43 USD
52W Low1.950 USD
Profitability
Gross Margin99.34%
Oper. Margin-120.41%
EBITDA Margin-141.92%
Profit Margin-310.18%
ROE70.21%
ROA-70.01%
Growth
Revenue Growth93.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-304.94M $
CapEx (TTM)4.25M $
FCF Margin-112.53%
FCF Yield-2.26%
Net Debt871.03M $
Net Debt/EBITDA-3.70
Balance Sheet
Debt/Equity-1.04
Current Ratio5.72
Quick Ratio5.36
Book Value/Sh-0.9940 USD
Cash/Share0.3370 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)12.75 USD
Upside (mean)+63.7%
Target Range12.00 USD – 15.00 USD
$12.00+63.7% to mean$15.00
# Analysts4
Ownership
Shares Out.1.06B
Float406.64M
Insiders62.17%
Institutions19.78%
Short Interest
Short Ratio12.8d
Short % Float32.18%
Short % Out.12.17%
Shares Short129.00M
Short (prev mo.)131.83M
Technical
SMA 507.711 (+1.0%)
SMA 2006.273 (+24.2%)
Beta0.13
S&P 52W Chg18.16%
Avg Vol (30d)8.78M
Avg Vol (10d)7.01M
Technical Indicators
RSI (14)53.0
MACD0.0537
MACD Signal-0.0347
MACD Hist.+0.0884
BB Upper8.114 USD
BB Middle7.405 USD
BB Lower6.697 USD
BB Width19.14%
ATR (14)0.4174 USD
Vol Ratio (20d)0.85x